High-quality sepsis care hinges on early recognition and treatment. Sepsis management is both time-sensitive and complex, depending on streamlined processes that start before a patient arrives at the hospital, with prehospital sepsis screening, and continue through discharge. The Surviving Sepsis Campaign (SSC) guidelines distill available evidence into actionable recommendations aimed at helping clinicians navigate these complex processes and manage patients based on the most up-to-date evidence.1 The new SSC guidelines, released in March 2026, provide 129 statements covering topics ranging from screening and early management to coordinating hospital discharge and addressing long-term outcomes.
Understanding guidelines
To understand how to apply the SSC guidelines in practice, it is important to understand why and how these guidelines are developed. The SSC guidelines, which are sponsored by the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) and endorsed by numerous multidisciplinary societies, are updated approximately every four years to capture new evidence and changing practices. The guidelines represent a massive undertaking by a diverse group of clinicians from around the world, including physicians across subspecialties, nurses, pharmacists, and physical therapists. For each selected topic, the committee conducts a systematic review of the literature and develops recommendations based on structured grading of the evidence, as outlined in the “Table of Statements” in the guideline publication.1
Despite this rigorous process for development, the SSC guidelines have been met with unfortunate backlash recently. In the United States, conditional recommendations from prior guidelines were translated into sepsis management bundles (SEP-1) that are now used as value-based purchasing, or pay-for-performance, measures by the US Centers for Medicare and Medicaid Services (CMS). This has blurred the line between guidelines and policy and resulted in accusations that the SSC guidelines are causing harm by mandating early antibiotics and aggressive fluid resuscitation.
Such framing misconstrues the intent of the SSC guidelines, which were developed to help bedside clinicians care for individual patients based on current evidence. The SSC guidelines aim to inform practice through feasible and broadly applicable recommendations that can be implemented across clinical settings.
These recommendations are not meant to be absolute. Rather, they often allow for nuance and acknowledge the realities of balancing complex factors involved in decision-making.
Guidelines breakdown
Most statements in the 2026 guidelines (63%) are “Conditional” recommendations, meaning they are based on low-to-moderate-quality evidence and are best framed as suggestions. Conceptually, it is reasonable to apply these recommendations for most patients, though shared decision-making and consideration of the clinical context may alter treatment.
In contrast, there are 19 “Strong” recommendations, which are typically based on higher-quality evidence and represent interventions that should be given to all, or nearly all, patients. For example, early antibiotic therapy and de-escalation of antibiotics after culture data return are both strong recommendations.
The 2026 SSC guidelines also offer a helpful new category of “In Our Practice” statements, which were made when there was very low certainty evidence for a topic. “In Our Practice” statements were developed by surveying the guideline panelists about their practices. For example, of the 69 panel members, 87% use peripheral vasopressors at least occasionally and 37% routinely treat patients with septic shock without invasive arterial blood pressure monitoring. While these statements in no way indicate that these are the best practices, they provide useful context to understand the clinical landscape in areas where evidence is less robust.
Notable recommendations
Overall, the updated SSC guidelines emphasize the importance of clinical evaluation, monitoring, and nuanced decision-making in the balance of risks and benefits of therapy. The guidelines encourage pairing proactive screening and early treatment with thoughtful approaches to diagnostic evaluation and antimicrobial stewardship. This helps clinicians navigate the challenge of time-sensitive management while avoiding overdiagnosis and overtreatment.
In particular, the guidelines highlight the importance of proactive screening and make a new conditional recommendation to screen patients for sepsis en route to the hospital (ie, in the ambulance or in flight). Simultaneously, the guidelines also acknowledge that there is no ideal sepsis screening tool, meaning not all patients with a positive screen have sepsis and should receive treatment. Therefore, the guidelines make a new conditional recommendation for the use of sepsis huddles or code sepsis teams—structured processes for responding to positive sepsis alerts—emphasizing that screening should prompt a clinical evaluation to inform treatment decisions.
Similarly, while the recommendation for time-to-antibiotics has not changed, the updated guidelines take two major steps to clarify this recommendation and minimize unwanted harms of antibiotic treatment.
First, the updated guidelines more clearly define “definite,” “probable,” and “possible” sepsis. Based on these definitions, the guidelines recommend antibiotics within one hour for all patients with definite sepsis (meaning sepsis is confirmed, eg, by positive blood cultures) or probable sepsis (meaning sepsis is number one on the differential), which aligns with clinical decision-making. For patients with possible sepsis (meaning sepsis is one of several diagnoses on the differential), antibiotics are recommended only within one hour for patients in shock, where shorter time-to-antibiotics has a stronger association with mortality and there is less room for error.
Second, the guidelines balance the recommendation for rapid antibiotics with an increased focus on stewardship, emphasizing both appropriate upfront antibiotic selection and de-escalation of antibiotic therapy once culture data become available. While critics have raised concerns that the SSC recommendation for rapid antibiotics will lead to overprescription and increased resistance, this has not been borne out in the literature, where studies have found no evidence of overtreatment when hospitals or clinicians deliver antibiotics more quickly.2,3 However, appropriate antibiotic selection is key to preventing unnecessary harms of treatment.
The 2026 guidelines include a new conditional recommendation against empiric antianaerobic coverage for infections unlikely to be caused by anaerobic pathogens—for example, respiratory and urinary tract infections, based on evidence that antianaerobic antibiotics alter the microbiome and may be associated with increased mortality.4 The guidelines also suggest against empiric antifungal coverage, highlighting that fungal coverage should be considered on a case-by-case basis.
The 2026 SSC guidelines for fluid resuscitation also emphasize the need to balance the risks and benefits of fluid through thoughtful application and de-escalation. The updated guidelines make an unchanged conditional recommendation for 30 mL/kg initial IV fluid for patients with sepsis-induced hypoperfusion (hypotension or elevated lactate) or shock. While this fluid volume is reasonable in most patients, the guidelines highlight the importance of considering individual patient characteristics in fluid decisions and the need for frequent, ongoing reassessments, preferably using dynamic measures such as passive leg raise, to prevent fluid overload. The guidelines also make a new conditional recommendation for “active fluid removal”—the use of diuretics or ultrafiltration to remove excess fluid—following the acute resuscitation phase in patients with signs of fluid overload. Together, these updates acknowledge the potential risks of fluid and highlight the importance of close monitoring and active management.
Additional considerations
There are several other new and revised recommendations in the 2026 SSC guidelines that warrant brief mention. First is the conditional recommendation to target an initial mean arterial pressure (MAP) of 60-65 mmHg, rather than ≥65 mmHg, in patients over 65 years old. While this recommendation was made based on evidence that lower MAP targets can spare vasopressors and potentially improve mortality in older patients, for now CMS still requires a MAP goal of 65 mmHg, complicating the implementation of this recommendation.5
Second, the guidelines now make a strong recommendation for extended β-lactam infusions based on accruing moderate certainty evidence that extended infusions increase time above the minimum inhibitory concentration (MIC) and improve antibiotic efficacy.6 This recommendation reflects an important opportunity for clinicians to review their local practice and consider modifications to antibiotic order sets to default β-lactam orders to extended infusions after the initial loading dose.
Finally, the guidelines make a conditional recommendation for selective decontamination of the digestive tract for mechanically ventilated patients in settings with low rates of antimicrobial resistance. Selective decontamination of the gut is an infection prevention strategy that involves the use of topical and targeted IV antibiotics aimed at eliminating pathogenic bacteria while maintaining the microbiome. While the data supporting selective decontamination are promising, with meta-analyses showing lower rates of infection and mortality, implementation warrants careful consideration at the local hospital level, in consultation with infection prevention specialists, to understand potential risks and benefits based on local epidemiology and resistance patterns.7
High-quality sepsis care
In summary, the 2026 SSC guidelines reaffirm that sepsis management is both time-sensitive and nuanced. The guidelines provide a practical framework to support early sepsis recognition and treatment, while emphasizing the importance of clinical evaluation, monitoring, and stewardship, providing a strong foundation for high-quality, patient-centered sepsis care.
This article was originally published in the Fall 2026 issue of CHEST Physician.
References
1. Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Crit Care Med. 2026;54(4):725-812. doi:10.1097/CCM.0000000000007075
2. Wayne MT, Seelye S, Molling D, et al. Temporal trends and hospital variation in time-to-antibiotics among veterans hospitalized with sepsis. JAMA Netw Open. 2021;4(9):e2123950. doi:10.1001/jamanetworkopen.2021.23950
3. Peltan ID, Groat D, Butler J, et al. Physician variation in early sepsis management. JAMA Netw Open. 2026;9(2):e2556945. doi:10.1001/jamanetworkopen.2025.56945
4. Chanderraj R, Admon AJ, He Y, et al. Mortality of patients with sepsis administered piperacillin-tazobactam vs cefepime. JAMA Intern Med. 2024;184(7):769-777. doi:10.1001/jamainternmed.2024.0581
5. Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. JAMA. 2020;323(10):938. doi:10.1001/jama.2020.0930
6. Abdul-Aziz MH, Hammond NE, Brett SJ, et al. Prolonged vs intermittent infusions of β-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis. JAMA. 2024;332(8):638-648. doi:10.1001/jama.2024.9803
7. Hammond NE, Devaux A, Vlok R, et al. Selective decontamination of the digestive tract in adult mechanically ventilated patients – an updated systematic review with Bayesian meta-analysis. NEJM Evid. 2026;5(5):EVIDoa2500264. doi:10.1056/EVIDoa2500264
